论文部分内容阅读
目的探讨核受体相互作用蛋白(NRIP3)在乳腺癌组织中的表达及与淋巴结阴性乳腺癌无远处转移生存的关系。方法利用BRB-Array Tools软件分析165例乳腺癌芯片中NRIP3基因表达水平,Kaplan-Meier法计算不同表达水平的无远处转移生存率,并进行Log-rank检验;应用Cox比例风险回归模型行多因素分析。结果 NRIP3基因低、中、高表达组中位无远处转移生存期(DMFS)分别为(3 980±331)d、(4 391±246)d、(4 518±147)d,Logrank检验生存曲线差异有统计学意义(χ2=7.847,P<0.05),多因素Cox模型分析显示,NRIP3基因高表达是乳腺癌远处转移独立的保护因素(P<0.01,Exp(B)=0.387)。雌激素受体(ER)阳性患者中NRIP3高表达率为41.2%(42/102),ER阴性患者中NRIP3高表达率为20.6%(13/63),差异有统计学意义(χ2=7.427,P<0.05);ER阳性的乳腺癌患者中,低表达NRIP3基因组的DMFS为(4 191±366)d,明显低于中表达组和高表达组(χ2=7.268,P<0.05),在ER阴性的乳腺癌患者中差异无统计学意义(χ2=0.524,P>0.05)。结论 NRIP3基因高表达可抑制淋巴结阴性乳腺癌发生远处转移,其发挥作用与ER阳性表达以及可能的内分泌治疗关系值得进一步研究。
Objective To investigate the expression of nuclear receptor interacting protein (NRIP3) in breast cancer and its relationship with distant metastasis of lymph node-negative breast cancer. Methods The BRIP-Array Tools software was used to analyze the expression of NRIP3 gene in 165 breast cancer samples. Kaplan-Meier method was used to calculate the survival rates of distant metastasis at different expression levels. Log-rank test was performed. Cox proportional hazards regression Factor analysis. Results The median long-term survival (DMFS) of NRIP3 gene in low, medium and high expression group were (3 980 ± 331) d, (4 391 ± 246) days and (4 518 ± 147) days respectively (Χ2 = 7.847, P <0.05). Multivariate Cox model analysis showed that high expression of NRIP3 gene was an independent protective factor of distant metastasis of breast cancer (P <0.01, Exp (B) = 0.387). The high expression rate of NRIP3 in ER-positive patients was 41.2% (42/102), and the high expression rate of NRIP3 in ER-negative patients was 20.6% (13/63) (χ2 = 7.427, (4 191 ± 366) d, which was significantly lower than that of the moderate expression group and the high expression group (χ2 = 7.268, P <0.05). In ER positive breast cancer patients, There was no significant difference between negative breast cancer patients (χ2 = 0.524, P> 0.05). Conclusion The overexpression of NRIP3 gene can inhibit the distant metastasis of lymph node-negative breast cancer. The role of NRIP3 gene in ERK3 expression may be related to ER-positive expression and possible endocrine therapy.